Artiva Biotherapeutics (ARTV) Other Non-Current Liabilities (2023 - 2024)
Artiva Biotherapeutics' (ARTV) quarterly Other Non-Current Liabilities came in at $73000.0 in Q4 2024, little changed year-on-year from $73000.0 in Q1 2024, and little changed on a QoQ basis from $73000.0 in Q3 2024.
Artiva Biotherapeutics (ARTV) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 2 years of Other Non-Current Liabilities data on file, last reported at $73000.0 in Q4 2024.
- On a quarterly basis, Other Non-Current Liabilities changed 0.0% year-over-year to $73000.0 in Q4 2024; TTM through Dec 2024 was $73000.0, a 0.0% change from a year earlier, with the FY2024 full-year figure at $73000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities for Q4 2024 stood at $73000.0, roughly flat from $73000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for ARTV reached as high as $74000.0 in Q2 2024 and fell as low as $73000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Artiva Biotherapeutics | 249.99 Mn | 249.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 73,000.00 |
| Jun 30, 2024 | 74,000.00 |
| Dec 31, 2023 | 73,000.00 |